#United States #Bethesda #Lung Cancer #LUNGevity Foundation #Sam Rogers

LUNGevity Foundation's New Leadership Announcement

The LUNGevity Foundation has made a significant stride in its fight against lung cancer by appointing Sam Rogers as the new Chief Development Officer. With nearly twenty years of experience in cancer philanthropy under his belt, Rogers arrives at a pivotal moment for the organization, which is focused on enhancing investments in research, advocacy, and programs that improve outcomes for individuals affected by lung cancer.

A Step Forward in Philanthropic Investment

The recent hire reflects LUNGevity’s ongoing commitment to bolstering the philanthropic funds necessary for advancing their mission. As advancements in early detection, precision medicine, and treatment become more pronounced, LUNGevity is dedicated to ensuring that groundbreaking science translates into tangible benefits for patients. Andrea Ferris, the Foundation’s president and CEO, remarked, "Driving meaningful change in lung cancer requires bold ideas, strong partnerships, and the resources to turn possibility into progress." With Rogers at the helm of development, LUNGevity aims to enhance its community ties while seeking new philanthropic partnerships.

Sam Rogers’ Vision for Lung Cancer

As the Chief Development Officer, Rogers will spearhead LUNGevity's comprehensive fundraising strategy. His role will involve nurturing existing relationships with donors and partners while also identifying new channels for philanthropic support. "There has never been a more critical time to invest in lung cancer," stated Rogers. His vision emphasizes sustained investment to harness the full potential of scientific discoveries and improve lives.

Rogers, before arriving at LUNGevity, held senior positions for four years at the American Association for Cancer Research (AACR) Foundation, where he was responsible for elevating their philanthropic strategies. Additionally, his tenure at the Lymphoma Research Foundation further honed his skills in fundraising and donor engagement. Both his educational background and professional experience set a solid foundation for his leadership at LUNGevity.

Building a Legacy of Impact

With a strong track record in fundraising and a dedication to advancing lung cancer initiatives, Rogers seeks to expand the Foundation’s efforts across various areas. This includes enhancing early detection, advancing precision medicine, improving access to clinical trials, promoting survivorship, and advocating for policies that benefit lung cancer patients. His overarching goal is to ensure patients and families have access to reliable information and support at every stage of their journey.

The need for proactive investment in lung cancer has never been more pressing. Experts note that approximately 229,000 Americans will be diagnosed with lung cancer this year alone, with alarming frequency—one new diagnosis every 2.3 minutes. Just as crucial, many of these new diagnoses occur among individuals with minimal to no past tobacco exposure. Amid these staggering statistics, LUNGevity's commitment to improving outcomes is essential.

Conclusion: A United Front Against Lung Cancer

LUNGevity Foundation stands as the largest nonprofit funder dedicated to lung cancer research in the United States. Its multifaceted approach intertwines research, patient support, and advocacy, aiming for comprehensive progress against the disease. As Rogers steps into his leadership role, the collective goal is to transform the narrative surrounding lung cancer, ensuring that individuals diagnosed can access innovative research, treatments, and meaningful support. The vision remains clear: a future where no one loses their life to lung cancer. For more information about LUNGevity Foundation and its initiatives, please visit www.LUNGevity.org.